Signature Estate & Investment Advisors LLC Acquires Shares of 2,402 Merck & Co., Inc. (NYSE:MRK)

Signature Estate & Investment Advisors LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRKGet Rating) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,402 shares of the company’s stock, valued at approximately $219,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Joseph P. Lucia & Associates LLC acquired a new position in shares of Merck & Co., Inc. in the first quarter valued at about $25,000. Landmark Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the first quarter valued at about $25,000. Front Row Advisors LLC grew its stake in shares of Merck & Co., Inc. by 89.4% in the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after acquiring an additional 160 shares in the last quarter. Okabena Investment Services Inc. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $27,000. Finally, Western Pacific Wealth Management LP acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $29,000. 73.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on MRK shares. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and upped their price objective for the stock from $95.00 to $100.00 in a research report on Wednesday, September 14th. Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They set a “buy” rating and a $100.00 price objective for the company. Morgan Stanley upped their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research report on Friday, July 29th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a “neutral” rating in a research report on Monday, July 18th. Finally, Atlantic Securities increased their target price on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.28.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $87.51 on Friday. The business has a 50 day moving average of $88.83 and a 200-day moving average of $87.81. Merck & Co., Inc. has a 1 year low of $71.50 and a 1 year high of $95.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15. The company has a market capitalization of $221.69 billion, a P/E ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. During the same quarter in the prior year, the firm posted $1.31 earnings per share. The firm’s revenue was up 28.0% compared to the same quarter last year. On average, equities research analysts predict that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be paid a $0.69 dividend. This represents a $2.76 annualized dividend and a dividend yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is currently 42.27%.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.